One Way Holdings LLC Sells 6,488 Shares of Natera, Inc. $NTRA

Key Points

• One Way Holdings LLC reduced its Natera stake by 7.9%, selling 6,488 shares and retaining 76,070 shares valued at approximately $31.4 million. Institutional investors collectively own 99.9% of Natera’s outstanding stock.
• Natera reported quarterly revenue of $752.75 million, up 37.7% year over year and above analyst expectations, while its quarterly loss of $0.47 per share narrowly beat estimates. Shares opened at $414.30, near their 52-week high of $437.41.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $394.31, although recent insider sales—including transactions by the CEO, CFO and other executives—could weigh on investor sentiment.

One Way Holdings LLC trimmed its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 7.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 76,070 shares of the medical research company's stock after selling 6,488 shares during the quarter. Natera accounts for 1.4% of One Way Holdings LLC's portfolio, making the stock its 21st largest holding. One Way Holdings LLC owned approximately 0.05% of Natera worth $31,440,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Greenleaf Trust acquired a new position in Natera during the 3rd quarter valued at $240,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Natera in the 3rd quarter worth $7,545,000. Profund Advisors LLC grew its position in Natera by 5.6% in the 3rd quarter. Profund Advisors LLC now owns 6,553 shares of the medical research company's stock worth $2,708,000 after purchasing an additional 348 shares during the last quarter. Vise Technologies Inc. grew its position in Natera by 5.3% in the 3rd quarter. Vise Technologies Inc. now owns 2,010 shares of the medical research company's stock worth $831,000 after purchasing an additional 101 shares during the last quarter. Finally, Americana Partners LLC bought a new position in shares of Natera during the 3rd quarter worth about $203,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Price Performance

Shares of Natera stock opened at $414.30 on Monday. The firm has a market capitalization of $59.72 billion, a PE ratio of -304.63 and a beta of 1.55. The company's fifty day moving average price is $377.06 and its two-hundred day moving average price is $266.44. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same period last year, the firm earned ($0.74) EPS. The firm's revenue for the quarter was up 37.7% compared to the same quarter last year. Analysts predict that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on NTRA shares. Robert W. Baird set a $348.00 price objective on shares of Natera in a research report on Friday, August 7th. BTIG Research lifted their target price on Natera from $320.00 to $430.00 and gave the stock a "buy" rating in a research report on Tuesday, October 27th. Roth Capital began coverage on Natera in a research note on Thursday, October 22nd. They set a "buy" rating and a $475.00 price target on the stock. Rothschild & Co Redburn initiated coverage on Natera in a research note on Tuesday, September 8th. They set a "buy" rating and a $385.00 price target on the stock. Finally, UBS Group upped their price target on Natera from $290.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $394.31.

Insider Buying and Selling at Natera

In other Natera news, insider John Fesko sold 6,517 shares of Natera stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the sale, the insider directly owned 197,257 shares of the company's stock, valued at approximately $63,424,043.21. The trade was a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 15,160 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40. Following the completion of the sale, the insider owned 110,859 shares in the company, valued at approximately $36,238,698.51. This represents a 12.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 45,734 shares of company stock worth $16,586,421. 5.05% of the stock is currently owned by company insiders.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Negative Sentiment: CFO Michael Brophy sold 1,178 shares at an average price of $426.46, generating approximately $502,370. The sale reduced his holdings by 2.37%, although it was executed under a pre-arranged Rule 10b5-1 trading plan, making it a less definitive signal about his outlook for Natera. SEC insider-trading filing
• Negative Sentiment: Additional filings reported multiple insider sales, including transactions attributed to Natera’s CEO, CFO and other insiders. The disclosed transaction values ranged from roughly $317,000 to $1.46 million, creating a broader pattern of insider selling that could weigh on sentiment. Natera insider-selling report
• Neutral Sentiment: Benzinga included Natera in its “Stock Whisper” index of companies attracting investor attention. The item provides visibility but no specific fundamental catalyst, forecast change or company announcement to directly support the shares. Benzinga Stock Whisper Index

Natera Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.